Literature DB >> 3484391

Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. V. Recognition is restricted to gene products encoded by the viral S RNA segment.

Y Riviere, P J Southern, R Ahmed, M B Oldstone.   

Abstract

Lymphocytic choriomeningitis virus (LCMV) Armstrong (ARM) strain-specific, H-2d-restricted CTL effectively lyse syngeneic targets infected by LCMV ARM, but show reduced killing of LCMV Pasteur (PAST) strain-infected H-2d cells. We have reassorted the two RNA segments, large (L) and small (S), of LCMV ARM and PAST to generate LCMV with genotypes of L ARM/S PAST and L PAST/S ARM. By using these reassortants and both LCMV primary CTL and CTL clones, we report that the induction, recognition, and lysis of LCMV-specific CTL depend on the S RNA segment and the genes it encodes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus.

Authors:  J L Whitton; J R Gebhard; H Lewicki; A Tishon; M B Oldstone
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Polymorphism of cytotoxic T-lymphocyte clones that recognize a defined nine-amino-acid immunodominant domain of lymphocytic choriomeningitis virus glycoprotein.

Authors:  E Joly; M Salvato; J L Whitton; M B Oldstone
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  The use of lymphocytic choriomeningitis virus reassortants to map viral genes causing virulence.

Authors:  Y Riviere; R Ahmed; M B Oldstone
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

4.  Restricted V-segment usage in T-cell receptors from cytotoxic T lymphocytes specific for a major epitope of lymphocytic choriomeningitis virus.

Authors:  Y Yanagi; R Maekawa; T Cook; O Kanagawa; M B Oldstone
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus.

Authors:  Andrew M Lee; Justin Cruite; Megan J Welch; Brian Sullivan; Michael B A Oldstone
Journal:  Virology       Date:  2013-05-16       Impact factor: 3.616

6.  Persistent virus infection associated with chemical manifestations of diabetes. II. Role of viral strain, environmental insult, and host genetics.

Authors:  A Tishon; M B Oldstone
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

7.  Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection.

Authors:  M B Oldstone; H Lewicki; P Borrow; D Hudrisier; J E Gairin
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

8.  Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes.

Authors:  J L Whitton; M B Oldstone
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

9.  Fine dissection of a nine amino acid glycoprotein epitope, a major determinant recognized by lymphocytic choriomeningitis virus-specific class I-restricted H-2Db cytotoxic T lymphocytes.

Authors:  M B Oldstone; J L Whitton; H Lewicki; A Tishon
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

10.  Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone.

Authors:  Saori Sakabe; Jessica N Hartnett; Nhi Ngo; Augustine Goba; Mambu Momoh; John Demby Sandi; Lansana Kanneh; Beatrice Cubitt; Selma D Garcia; Brian C Ware; Dylan Kotliar; Refugio Robles-Sikisaka; Karthik Gangavarapu; Luis M Branco; Philomena Eromon; Ikponmwosa Odia; Ephraim Ogbaini-Emovon; Onikepe Folarin; Sylvanus Okogbenin; Peter O Okokhere; Christian Happi; Pardis C Sabeti; Kristian G Andersen; Robert F Garry; Juan Carlos de la Torre; Donald S Grant; John S Schieffelin; Michael B A Oldstone; Brian M Sullivan
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.